Global Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Cognitive Impairment Associated With Schizophrenia (CIAS) treatment during 2019. Clinical development activities are being undertaken by more than 15 companies including Anvyl LLC, Astellas Pharma Inc, AstraZeneca Plc, Autifony Therapeutics Ltd, Biogen Inc and others.
A Significant contribution to the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline included 19 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Cognitive Impairment Associated With Schizophrenia (CIAS) condition and increased access to investments is encouraging growth of Cognitive Impairment Associated With Schizophrenia (CIAS) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Cognitive Impairment Associated With Schizophrenia (CIAS) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Cognitive Impairment Associated With Schizophrenia (CIAS) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Cognitive Impairment Associated With Schizophrenia (CIAS). Further, orphan drug status, fast track designation, grants awarded and other special status for Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline candidates-
A Significant contribution to the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline included 19 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Cognitive Impairment Associated With Schizophrenia (CIAS) condition and increased access to investments is encouraging growth of Cognitive Impairment Associated With Schizophrenia (CIAS) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Cognitive Impairment Associated With Schizophrenia (CIAS) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Cognitive Impairment Associated With Schizophrenia (CIAS) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Cognitive Impairment Associated With Schizophrenia (CIAS). Further, orphan drug status, fast track designation, grants awarded and other special status for Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Cognitive Impairment Associated With Schizophrenia (CIAS) drugs
- Late phase: Phase 3 and in-approval Cognitive Impairment Associated With Schizophrenia (CIAS) drugs
- Company overview
- Snapshot
- Cognitive Impairment Associated With Schizophrenia (CIAS) therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Cognitive Impairment Associated With Schizophrenia (CIAS)- Disease Overview
2.2 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pipeline Snapshot
2.3 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pipeline Drugs by Phase
2.4 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pipeline Drugs by Company
2.5 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Anvyl LLC Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.2 Astellas Pharma Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.3 AstraZeneca Plc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.4 Autifony Therapeutics Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.5 Biogen Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.6 Boehringer Ingelheim GmbH Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.7 Bristol-Myers Squibb Co Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.8 Cadent Therapeutics Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.9 Coronis NeuroSciences Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.10 Eli Lilly and Co Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.11 F. Hoffmann-La Roche Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.12 Iproteos SL Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.13 Pfizer Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.14 SK Biopharmaceuticals Co Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.15 Sosei Heptares Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.16 Spherium Biomed SL Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.17 Suven Neurosciences Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.18 Takeda Pharmaceutical Co Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.19 Vanda Pharmaceuticals Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 1 Drug Details
4.2 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 1 Drug Overview
4.3 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 2 Drug Details
5.2 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 2 Drug Overview
5.3 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 3 Drug Details
6.2 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 3 Drug Overview
6.3 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pre-clinical Phase Drug Details
7.2 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pre-clinical Phase Drug Overview
7.3 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Cognitive Impairment Associated With Schizophrenia (CIAS)- Disease Overview
2.2 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pipeline Snapshot
2.3 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pipeline Drugs by Phase
2.4 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pipeline Drugs by Company
2.5 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Anvyl LLC Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.2 Astellas Pharma Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.3 AstraZeneca Plc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.4 Autifony Therapeutics Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.5 Biogen Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.6 Boehringer Ingelheim GmbH Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.7 Bristol-Myers Squibb Co Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.8 Cadent Therapeutics Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.9 Coronis NeuroSciences Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.10 Eli Lilly and Co Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.11 F. Hoffmann-La Roche Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.12 Iproteos SL Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.13 Pfizer Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.14 SK Biopharmaceuticals Co Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.15 Sosei Heptares Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.16 Spherium Biomed SL Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.17 Suven Neurosciences Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.18 Takeda Pharmaceutical Co Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.19 Vanda Pharmaceuticals Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 1 Drug Details
4.2 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 1 Drug Overview
4.3 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 2 Drug Details
5.2 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 2 Drug Overview
5.3 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 3 Drug Details
6.2 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 3 Drug Overview
6.3 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pre-clinical Phase Drug Details
7.2 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pre-clinical Phase Drug Overview
7.3 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
